Rodent autonomous parvoviruses (PVs) are endowed with oncotropic properties and represent virotherapeutics with inherent oncolytic features. This work aimed to evaluate the capacity of Minute Virus of Mice (MVMp) to act as an adjuvant stimulating a mouse glioblastoma-specific immune response. MVMp was shown to induce cell death through apoptosis in glioma GL261 cells. Antigen-presenting cells (APCs) provide the initial cue for innate and adaptive immune responses, and thus MVMp-infected GL261 cells were tested for their ability to activate dendritic cells (DCs) and microglia (MG), two distinct cell types that are able to act as APCs. MG and discrete DC subsets were activated after co-culture with MVMp-infected glioma GL261 cells, as evidenced by upregulation of specific activation markers (CD80, CD86) and release of proinflammatory cytokines (tumor necrosis factor-a and interleukin-6). The in vivo analysis of immunodeficient and immunocompetent mice revealed a clear difference in their susceptibility to MVMp-mediated tumor suppression. Immunocompetent mice were fully protected from tumor outgrowth of GL261 cells infected ex vivo with MVMp. In contrast, immunodeficient animals were less competent for MVMp-dependent tumor inhibition, with only 20% of the recipients being protected, arguing for an additional immune component to allow full tumor suppression. In keeping with this conclusion, immunocompetent mice engrafted with MVMp-infected glioma cells developed a level of anti-tumor immunity with isolated splenocytes producing elevated levels of interferon-g. In rechallenge experiments using uninfected GL261 cells, we could show complete protection against the tumor, arguing for the induction of a T-cell-mediated, tumor-specific, long-term memory response. These findings indicate that the anticancer effect of PVs can be traced back not only for their direct oncolytic effect, but also to their ability to break tumor tolerance.
INTRODUCTION
Malignant brain tumors of glial origin are usually fatal, and only 50% of patients survive the first year after the diagnosis has been established. Recent modifications of standard treatments, including tumor removal, radiation therapy and chemotherapy, have only led to a modest improvement in the outcome of the disease.
1,2 Therefore, oncolytic viruses have been investigated as a novel and promising treatment against malignant brain tumors. In this regard, autonomous rodent parvoviruses (PVs), which have recently emerged as potential anticancer agents, deserve special attention. 3 This is because of their ability to replicate in and destroy cancer cells, while possessing low capacity for danger signalling and being innocuous to healthy tissues. 4 In particular, the oncolytic rat H-1PV was shown to selectively target and kill cells derived from various cancer types, including cells originating from human gliomas. 5 The concept of H-1PV-based virotherapy of glioma was successfully tested in vivo, using rat (RG-2) and human (U87) glioma cell implants in immunocompetent and immunodeficient rat models, respectively. 6 It has to be stated that the therapeutic effect of the virus was more pronounced in immunocompetent animals. Pioneering in vitro studies using a melanoma model have demonstrated that tumor cell killing by a wild-type H-1PV can directly stimulate the maturation of human dendritic cells (DCs) and antigen cross-presentation to cytotoxic T lymphocytes. 7 Our recent work using various animal models furthermore substantiates the contention that H-1PV acts as an oncolytic agent as well as an adjuvant, with both direct cytoreduction and bystander antitumor immunity playing a role in the anticancer action of this virus. 8 Although rats and hamsters have several advantages as H-1PV-permissive model species, they offer only a limited set of genetic and methodological tools to dissect immunological responses as compared with mouse models. This prompted us to choose, for the present proof-of-principle study, the prototype strain of Minute Virus of Mice (MVMp), another oncolytic PV, which is closely related to H-1PV but has a different host range, enabling its propagation in mouse tumors. 9 We initially hypothesized that virus-induced volatility (including lysis) of tumor cells may contribute to activate antigen-presenting cells (APCs), thereby stimulating the induction of an adaptive tumor-specific immune response. This study aims to analyze this hypothesis using MVMp and the established mouse GL261 glioma model. The GL261 cell line proved to be highly permissive for the killing effect of the virus. Furthermore, infection of these glioma cells with MVMp enhanced their capacity for activating cocultured mouse DC and microglia (MG) cells, as revealed by elevated expression of major histocompatibility complex class II (MHC II), CD80 and CD86 activation markers and the release of tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) cytokines.
In addition, in vivo assessment of tumorigenicity of transplanted MVMp versus MOCK-infected GL261 glioma cells into either immunodeficient RAG2
À/À or immunocompetent C57BL/6 mice gave evidence that the immune system, and in particular the T-cell-mediated adaptive response, played a crucial role in the anticancer effect of MVMp in this model.
MATERIALS AND METHODS Cells
The mouse glioma GL261 cell line was kindly provided by Geza Safrany (Department of Molecular and Tumor Radiobiology, Frederic Joliot-Curie National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary).
10 B16F10/GM-CSF and B16F10/FLT3 melanoma cells were provided by G Dranoff (Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA).
11 Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS; Biochrom, Berlin, Germany), 2 mM glutamine, 1% penicillin--streptomycin, 1 mM NEAA and 1 mM NaPyruvate (Invitrogen, Darmstadt, Germany). Cell viability was determined by 0.4% (w/v) Trypan blue (Sigma, Seelze, Germany) exclusion.
DCs were isolated from mouse spleen and lymph nodes from 7-to 12-week-old C57BL/6 female mice as described previously. 12 Briefly, C57BL/6 mice were injected subcutaneously (s.c.) with B16F10/GM-CSF or B16F10/ FLT3L cells (1 Â 10 6 cells per mouse in 100 ml phosphate-buffered saline (PBS)) 14 days before DC isolation from lymph nodes and spleen. Singlecell suspensions were prepared and red blood cells were lysed. Cells were washed twice and counted. To deplete non-DCs, the single-cell suspension was incubated with rat-anti-mouse CD4, CD8, B220, CD19 and CD3 antibodies, followed by labelling with sheep anti-rat IgG coupled to magnetic beads (Dynabeads, Invitrogen). Beads-coupled cells were eliminated on a magnetic column, and the residual cell suspension was spun down. Cells recovered derived from B16F10/GM-CSF-and B16F10/ FLT3L-injected mice were used as myeloid and lymphoid DCs in the following experimental settings. The purity of DC sub-populations was assessed by CD11c/b, MHC class II and CD8a surface labelling and followed flow cytometric analysis.
Primary MG cultures were prepared from newborn mouse brains as described by Burudi et al. 13 Briefly, the skullcap was opened medially, the brain was carefully removed and transferred into a tube containing 1 Â Hank's balanced salt solution. Meninges were removed under a stereoscope. Brains were then transferred into 50 ml poly-propylene tubes containing 10 ml complete DMEM (cDMEM). The brains were dissociated with trypsin-EDTA in the presence of DNAse (0.05%) for 20 min. The cells were spun at 1000 r.p.m. for 10 min, resuspended in cDMEM with antibiotics and plated in T75 flasks precoated with poly-L-lysine (20 mg ml À1 ) in 10 ml final volume. Cells were cultured at 37 1C in a 5% CO 2 atmosphere, with medium changes on days 1, 2 and day 7 after plating. At day 14, adherent cultures, consisting of a mixture of astrocytes and MG, were treated with trypsin-EDTA for 5 min at 37 1C. After addition of cDMEM plus DNAse (0.05%), cells were easily detached using a Pasteur pipette, washed and replated in 6 cm dishes at 37 1C, 5% CO 2 . After 1 h of incubation, MG adhered whereas astrocytes remained in suspension and were transferred to graded dishes for further culturing. Before use, cultures of astrocytes and MG were kept for 14 and 21 days after replating, with medium change once a week.
Virus production and titration
The prototype strain of MVMp was produced infecting 293T cells, purified through iodixanol gradient centrifugation and dialyzed against Ringer solution as described by Zolotukhin et al.
14 Virus stocks were titered using a standard plaque assay, and titers were expressed as plaque forming units (pfu ml À1 ). 
Southern blotting

Flow cytometric analysis
Splenocytes were prepared by mechanical disruption of whole spleens, and red cells were lysed in Gey's solution. Splenocytes, DCs and MG cell suspensions were passed through 70 mm filters, and incubated on ice for 30 min with anti-mouse CD16/CD32 (Fcg RII/III) blocking antibodies in FACS buffer (2% FCS in Hank's balanced salt solution). Surface staining was performed for 45 min on ice, using specific antibodies (BD Pharmingen, Heidelberg, Germany): CD11c, CD11b, CD4, CD8, CD3, B220, NK1.1, CD80 and CD86, which were coupled by fluorescein isothiocyanate, phycoerythrin and APC fluorochromes. Cells were analyzed using CellQuest software and a FACSCalibur cytometer (BD Biosciences, Heidelberg, Germany).
Intracellular expression of nonstructural protein 1 (NS-1)
Mouse glioma GL261 cells were infected with MVMp at indicated multiplicities of infection (MOIs) and incubated for 24--96 h. After trypsinization, they were fixed in 4% cold formaldehyde for 15 min at room temperature, washed with PBS containing 0.1% bovine serum albumin, resuspended in 80% ice-cold methanol in PBS 2 Â 10 6 cells per sample and incubated overnight at À20 1C. After further washes with cold PBS and then PBS containing 0.1% bovine serum albumin, cells were permeabilized by two washes with PBAT (PBS supplemented with 0.1% BSA (w/v), 0.04% sodium azide, 0.5% Tween 20) at room temperature. After blocking for 30 min at 4 1C in PBS supplemented with 40% donkey serum, staining with NS-1-specific antibodies (clones 2C9 and 3D9 mixed in a 1:10 final dilution each) was performed for 45 min at 4 1C, followed by three washes in PBAT and incubation with secondary R-phycoerythrin-conjugated donkey anti-mouse antibodies for 60 min at 4 1C. After two washes in PBAT, cells were filtered and analyzed by flow cytometry on a FACScan (BD Biosciences). Data were processed by using the CellQuest software package.
Intracellular staining for interferon-g (IFN-g) by flow cytometry Splenocytes were collected at day 14 both from C57BL/6 mice bearing tumors of noninfected GL261 transplants (MOCK, n ¼ 5) and rechallenged mice from the MOI 30-treated group (MOI 30, n ¼ 5), which had been challenged with noninfected GL261 cells (1 Â 10 6 per animal) 60 days after tumor cell implantation. Single-cell suspensions were prepared and red cells were lysed in Gey's solution. Splenocytes were cultured with irradiated glioma GL26 cells at a ratio of 10:1 for 48 h. At 6 h before cell harvest, 10 mg ml À1 of brefeldin A (Sigma) was added. Cells were harvested, washed in the presence of brefeldin A (PBS, 5 mg ml À1 of brefeldin A) and stained using anti-CD8 and anti-CD3 antibodies (BD Pharmingen). Labelled cells were then fixed with 2% paraformaldehyde. After washing with PBS/ 1% FCS and 10 min of incubation in CytoPerm medium (BD Pharmingen), cells were incubated for 30 min at room temperature with the appropriate concentration of anti-IFN-g monoclonal antibodies. After three washes in PBS/1% FCS, the cells were resuspended in 500 ml PBS/1% FCS. Data were collected on 2 Â 10 4 CD8 þ cells using a FACSCalibur cytometer and analyzed using the CellQuest software.
Cytotoxicity assay
To assess cytotoxicity, cells were seeded in 96-well plates (Nunclon, Nunc, Germany) at a density of 2 Â 10 4 per well, and treated as indicated. Cell viability was determined by the colorimetric 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, as recommended by the manufacturer (Sigma).
Caspase-3 activation
Caspase-3 activation was determined as previously described by Di Piazza et al. 5 by adding 25 ml of whole-cell extract to caspase buffer (50 mM Hepes (pH 7.4), 150 mM NaCl, 0.1% CHAPS, 0.1% Triton X-100, 1 mM EDTA, 10% Glycerol, 10 mM DTT) supplemented with caspase 3 substrate (Ac-Asp-GluVal-Asp-AFC) at 1 mM concentration (Calbiochem, Darmstadt, Germany). The reaction was monitored for 1 h on a Fluoroscan (Thermo Labsystems Fluoroscan; Thermo Labsystems, Thermo Scientific, Erlangen, Germany) using excitation and emission wavelength of 390 and 510 nm, respectively.
TNF-a and IL-6 measurement
Culture supernatant samples (100 ml) were analyzed in triplicate for TNF-a and IL-6 as determined by enzyme-linked immunosorbent assay using the OptEIA Set Mouse (BD Pharmingen) according to the manufacturer's instructions.
ELISPOT assay IFN-g secretion by individual cells was assessed using standard enzyme-linked immunosorbent spot (ELISPOT) protocol. 16 Specific anti-mouse IFN-g antibodies (BD Pharmingen, 551216), and biotinylated rabbit anti-mouse IFN-g antibody (BD Pharmingen, 554410) were used for cell capturing and IFN-g detection, respectively. Spots were visualized with the BCIP/NBT Liquid Substrate system (Sigma, B1911) according to the manufacturer's instructions.
In vivo tumor model C57BL/6 and RAG2
À/À mice were purchased from Charles River (Sulzfeld, Germany) and bred in the DKFZ animal facility. All animals were kept in isolators under standard conditions (temperature of 22 ± 2 1C, relative humidity of 55 ± 10%, 12 h dark/12 h light cycle) with unrestricted access to a balanced pellet diet and water. Animal experiments were performed according to the German and European Community directives for animal care (86/609/EEC, 24 November 1986). Tumor development in vivo was induced by transplanting 1 Â 10 6 GL261 cells, which were ex vivo infected with MVMp at indicated MOIs or MOCK-treated, incubated for 4 h before transplantation and injected s.c. subsequently into the right flanks of C57BL/6 or RAG2 À/À mice. Tumor development was monitored by measuring tumor size two to three times a week and the tumor volume was calculated for an ellipsoid using the formula V ¼ p/6 Â length Â width Â height (mm 3 ). Animals were killed for ethical reasons when the tumor volume exceeded 1.2--1.5 cm 3 . The tumor sizes measured on animals with 3000 mm 3 were obtained from the animals that were killed by the care takers of the animals.
Statistical methods
In vitro data represent mean values with s.d. from three independent experiments. The statistical significance of differences was assessed by one-tailed Student's unpaired t-test.
RESULTS
Permissiveness of glioma GL261 cells for MVMp infection
To assess the therapeutic efficacy of MVMp in glioma cells, it had to be established whether these cells are permissive for virus infection, replication and whether MVMp can exert its oncolytic effect in these cells. The ability of MVMp to infect the GL261 glioma cell line was determined in vitro by measuring viral replication and cytotoxicity, as a function of time after inoculation of virus at different MOIs. Southern blotting analysis of low-molecular-weight DNA extracted early (6 h) after infection showed the presence of cell-associated input viral singlestranded DNA (Figure 1a ), indicating that GL261 cells were competent for MVMp uptake. These cells could also support MVMp DNA replication, as evidenced by formation and amplification of double-stranded DNA replicative forms of monomeric and dimeric size at later time points after infection ( Figure 1a) . Furthermore, expression of the cytotoxic parvoviral NS-1 protein steadily increased over time with a peak at 48 h after infection and declined afterwards (Figure 1b) . In order to determine whether MVMp infection affected GL261 cell viability, MTT assays were carried out, revealing that MVMp was toxic for these cells in a time-and dose-dependent manner (Figure 1c ). Approximately 90% of the cell population was dead 3 days after MVMp infection at a MOI of 10 pfu per cell. Most likely, the downregulation of the NS-1 protein expression at day 3 after infection occurs because of the tremendous cell death at this time point. It is known that rodent PVs can kill cells by necrosis and/or apoptosis, depending on the type and physiological conditions of target cells. 17 This prompted us to test whether MVMp infection of GL261cells resulted in caspase-3 activation and DNA fragmentation, two markers of apoptosis. As illustrated in Figure 1d , noninfected glioma GL261 cells showed a constant basal caspase-3 activity within the time interval studied, whereas the enzyme activity was increased up to fivefold at 48 h after MVMp inoculation, when massive cell death takes place. Caspase-3 activity declined at the later time points, most likely because of the resistance of small population of cells toward MVMp (o10%). Infected GL261 cells also underwent typical DNA fragmentation at 72 and 96 h after infection (80% of DNA fragmentation; data not shown). Thus, glioma GL261 cells were sensitive to the cytotoxic activity of MVMp and showed apoptotic features of cell death after virus infection.
MVMp infection activates DCs and MG It is well established that activation of APCs is the first step to initiate innate and adaptive immune responses. Therefore, we further investigated whether major APC populations such as myeloid and lymphoid DCs and MG could be activated as a result of their direct infection with MVMp and/or their interaction with apoptotic GL261 cells infected with MVMp.
DCs were obtained either after in vivo activation in a mouse tumor model, 11 or by in vitro selection, yielding myeloid and lymphoid subpopulations that were 85--95% pure as determined by cell surface marker profiles (data not shown). As these DC subpopulations were highly proliferative, the question arose whether they were susceptible to MVMp infection and subsequent oncolytic lysis. This issue was of clear relevance to the present clinical developments of PVs as cancer therapies. As shown in Figure 1a (left panel), Southern blot analysis of highly enriched DC subpopulations infected with MVMp provided evidence of viral entry (presence of cell-associated input viral genomes at early times after infection) but failed to reveal any detectable viral DNA amplification (absence of duplex replicative forms at later time after infection). These data extended the previous observations that MVMp can enter but not replicate in brain-derived APCs, the so-called MG. 18 It was further investigated whether high MOI of MG, naive or mature DC subpopulations with MVMp may alter the expression of distinct activation markers in these cells. MVMp infection had no significant impact on the activation of naïve lymphoid/myeloid DCs and MG, as illustrated in Figure 2 Figure S1) . Therefore, it appeared that although APC infection with MVMp is abortive, the entry of the virus in these cells might still mobilize, although inefficiently, signalling pathways to induce cytokine production and further activation of DCs and MG.
DCs) in lipopolysaccharide (LPS)-treated cultures (compare DC þ LPS with DC þ LPS þ MVMp) (Supplementary
We next assessed whether incubation with MVMp-infected GL261 glioma cells could activate naive APCs, which failed to respond to direct MVMp infection. As shown above, these cells were indeed permissive for PV replication, and may release viral factors and/or virus-induced cellular factors that are sensed by APCs and stimulate their maturation. As illustrated in Figures 2a  and b , limited activation of DCs was detected following their exposure to intact or lysed (through repeated freezing and thawing (F/T)) uninfected GL261 cells (compare DC alone with DC þ GL MOCK or DC þ GL F/T, respectively). This activation was significantly enhanced when DCs were co-cultured with MVMpinfected GL261 cells (compare DC þ GL MOCK/F/T with DC þ GL MVMp), indicating that MVMp enhanced the capacity of glioma cells for DC maturation through a mechanism that was indeed not limited to mere lysis of these cells. MG cells also responded to the activation effect of MVMp-infected GL261 cells, yet to a lower extent compared with DCs. These data were substantiated by showing that MVMp infection of GL261 cells increased their ability to induce the secretion of TNF-a (from lymphoid DCs and MG) and IL-6 (from myeloid and lymphoid DCs and MG), thereby pointing to additional autocrine/paracrine signals for maturation of these cells (Figures 2c and d , compare DC/MG þ GL MOCK/F/T with DC/ MG þ GL MVMp).
Taken together, these in vitro results demonstrated significant activation of DCs and MG upon incubation with MVMp-infected GL261 glioma cells. This prompted us to assess whether MVMp may also act as an adjuvant under in vivo conditions, and endow infected GL261 glioma with an enhanced capacity for priming a tumor-specific adaptive immune response.
Immune-mediated suppression of MVMp-infected GL261 tumors GL261 glioma cells were infected in vitro with MVMp or MOCK treated, incubated for 4 h and injected s.c. into either immunocompetent mice (C57BL/6) or into RAG2 À/À mice deficient of B and T cells. First signs of tumor development were detected at day 5 after implantation in both wild-type C57BL/6 and RAG2 À/À mice. In the immunocompetent C57BL/6 mice, MOCK-treated GL261 transplants all developed into tumors by day 35, whereas tumor transplants infected with MVMp at a MOI X3 pfu per cell all regressed (Table 1 and Figure 3a) . Thus, all C57BL/6 mice engrafted with GL261 cells pre-infected with MVMp at MOI of 3 or 30 pfu per cell survived in the long term (until the end of the experiment, for at least 6 months), with no sign of late tumor development (Table 1) . In contrast, all RAG2 À/À animals transplanted GL261 cells eventually developed tumors by day 35 after transplantation irrespective of whether the glioma cells were infected or not with MVMp (Table 1) . MVMp infection of GL261 glioma prolonged in a MOI-dependent manner the repression of tumor growth in RAG2 À/À mice (Figure 3b) . However, the formation of tumors occurred eventually, most likely because of the small percentage of intrinsically virus resistant cells, which gave rise to tumor growth.
Altogether, these observations indicate that the ability of MVMp to suppress GL261 glioma tumor growth depends on the proper functioning of the host immune system. The PVs and immune system appear to act synergistically to eliminate these tumor cells under conditions in which each component alone is inefficient. The specific defect of RAG2 À/À animals to mount B-and T-cell responses indicate the involvement of either of these arms of the immune system in cooperation with PVs, and more particularly of the T-cell branch that is known to play a crucial role in anticancer defences. The question then arises of how PVs and T-cell immunity may cooperate to inhibit the progression to glioma tumor formation. One possibility, supported by the results presented in the previous section, would be that PV infection leads tumor cells to activate the immune system that takes over from the direct viral oncolytic effects to complete tumor destruction. Another nonexclusive possibility would be that the immune system limits the rate of tumor cell proliferation, thus providing progeny virions produced by primarily infected tumor cells time to induce secondary rounds of infection at a multiplicity high enough to cause oncolysis. To distinguish between these two possibilities, we tested whether the gliomas developing in RAG2 À/À mice despite their high MOI infection with MVMp have still kept the same sensitivity to the virus as the original GL261 cell line. For this purpose, developing tumors were isolated from mice implanted with MVMp or MOCK-treated glioma cells. Single-cell suspensions were prepared and tested either immediately or after 30 days of culture in vitro for their sensitivity to MVMp in comparison with the original GL261 cell line. As shown in Figure 3c , cells isolated from MOCK or MVMp-treated tumors growing from either mouse strain proved to be much more resistant to the killing effect of MVMp than the parental GL261 line. This observation indicated that as a result of their in vivo passaging, the glioma cells lost their sensitivity to the PV-induced oncolytic effect and their evasion from oncolysis was not because of virus dilution in rapidly growing tumors. Altogether, these data argue that the elimination of MVMp-infected gliomas in C57BL/6 but not in RAG2 À/À mice was not because of enhanced intratumoral virus dilution in the healthy animals but that at least part of the PV-dependent oncosuppression was actually carried out by immune cells (most likely T cells). In this tumor model, MVMp appeared to act as an adjuvant stimulating an anti-glioma cellular immune response.
Development of an adaptive anti-glioma memory response in mice devoid of tumor burden after MVMp treatment In order to substantiate this conclusion, we searched for evidence of a glioma-specific cellular immune response in C57BL/6 mice undergoing MVMp-induced tumor regression. In a first step, splenocytes were isolated from animals implanted with MVMp-infected or MOCK-treated GL261 cells, and compared for their immune subpopulations by flow cytometry. As shown in Supplementary Table S1 , no significant differences were observed between splenocytes of mice in either the total amount of immune cells or the relative populations of T and B cells, natural killer cells and DCs. These data were correlated by flow cytometry analysis of tumors infiltrated with immune cells, showing a major but similar recruitment of leukocytes by both MVMp-infected and control tumors (data not shown). These observations were in keeping with the above conclusion that the immune system restricted the growth of GL261 gliomas in C57BL/6 mice. It supported further the notion that the full suppression of infected tumors in these animals resulted from the MVMp-dependent functional activation of tumor-specific T-cell subsets. This possibility was tested by determining whether splenocytes from C57BL/6 mice implanted with MVMp-infected gliomas (as compared with MOCK-treated tumors) contained a greater fraction of cells that were able to mount an IFN-g response when brought into contact with glioma cells. IFN-g release was monitored isolating splenocytes from C57BL/6 mice 14 days after implantation of MVMp vs MOCK-treated GL261 cells, and subjecting them to ELISPOT assay after stimulation with uninfected glioma cells. As illustrated in Figure 3d , the median of splenocytes reacting to the tumor cells by producing IFN-g was increased twofold in mice carrying MVMp-infected (compared with MOCK-treated) glioma cells. Furthermore, this slight but reproducible increase in IFN-g-producing effector cells was recapitulated in the rechallenge situation. We compared the absolute number of the main T-cell populations in recipients receiving MOCK-treated GL261 cells versus the number of T cells obtained from rechallenged animals. Both groups were analyzed 14 days after tumor challenge. We observed a significant increase in all T-cell fractions, but not in natural killer cells. In addition, we could detect specifically a significant increase of IFN-g-producing CD8
þ T cells in the MVMp-treated mice (Figure 3e ). These results indicate that the infection of tumor cells with MVMp can lead to a long-lasting antitumor cellular immune response in C57BL/6 mice.
To produce further proof to the adjuvant effect of the PVs, longterm survivors of MVMp-infected tumor implantation, cured of their tumor burden through the PV treatment (GL261 cells ex vivo infection at a MOI of 0.3), were rechallenged with uninfected GL261. In contrast to naive C57BL/6 mice that all developed tumor after implantation of MOCK-treated GL261 cells (see above), all MVMp-cured animals (n ¼ 6) remained tumor free over an observation period of 5 months after the initial challenge (Table 1) .
Taken together, our results demonstrate that in this particular tumor model MVMp infection of implanted GL261 cells induces a glioma-specific immune memory response in immunocompetent mice, which was likely to be T-cell mediated. This conclusion is further supported by the activation of IFN-g-producing cells and the defect of RAG2 À/À animals mounting a PV-dependent tumor suppression.
DISCUSSION
The present work shows that the antitumor cellular immune response plays an important role in the oncosuppressive effect of MVMp in the GL261 mouse glioma model. This immune contribution is in accordance that PV oncolysis may be expected to result in the release of tumor-associated antigens and possibly also of pathogen-and damage-associated molecular patterns. Such events have been shown to stimulate presentation of these antigens and priming of an antitumor immune response. 19 It is thus important to understand the mechanisms of autonomous PV oncosuppression and especially its immune components. In particular, as other oncolytic viruses are presently under consideration for innovative cancer therapeutic approaches. Focusing therefore on a glioma model relates to the current launching of a first clinical trial using H-1PV in glioma patients.
The mouse tumor model used in this study is based on the glioma cell line GL261. The analysis of MVMp/GL261 cell interaction showed that the virus was able to infect and replicate efficiently in this tumor line. At 2 to 3 days after infection, the majority of glioma GL261 cells had lost their adherence properties and underwent apoptosis. Surprisingly, in vivo injection of MVMp-pre-infected GL261 cells led to tumor formation, and these cells revealed a striking decrease of their permissiveness for MVMp replication and cytopathic effects. It thus appeared that in the in vivo microenvironment GL261 cells became much less sensitive to the direct oncolytic activity of PVs. MVMp was still able to induce a full suppression of GL261 tumor in immunocompetent but not immunodeficient mice, raising the likelihood that the immune system took over from the initial oncolytic effect of the virus to complete the elimination of tumor cells. This led us to address the issue of whether MVMp had immunomodulatory properties and could act as an adjuvant to stimulate immuno-mediated tumor rejection, thereby accounting for the synergistic effect of the PV and host immunocompetence on glioma regression.
Depending on co-stimulatory signals, DCs can induce T-cell activation, anergy or tolerance. 20 Myeloid DCs represent promising tools for immunotherapy of tumors. In animal models and human clinical trials, adoptively transferred myeloid DCs expressing tumor antigens mediate substantial antitumor immunity. 21 Immature DCs take up and process pathogens, presenting their antigens on the cell surface using MHC molecules. These cells are characterized by high endocytic activity and low T-cell activation potential. Upon danger signalling, DC surface molecules such as CD80, CD86 and CD40 are upregulated and act as co-receptors in T-cell activation, greatly enhancing the ability of DCs to prime cellular immune response (reviewed in Mellman and Steinman 22 ). It was thus of interest to determine whether MVMp had a direct or indirect impact on DC cell maturation. This might affect the rate of s.c.-implanted gliomas in the tumor model studies. Furthermore, this analysis was extended to MG derived from newborn brain tissues, as microglial cells are representatives of glioma microenvironment, and are known to function as resident macrophages of the brain, endowed with capacities for antigen-presentation, phagocytosis and secretion of cytokines and chemokines. 23 In a first step, it was shown that MVMp was able to infect DCs but failed to replicate and exert cytopatic effects in these cells, although they proliferated, a prerequisite of the parvoviral life cycle. It should be noted that DCs normally have low proliferative potential, unless challenged with stimulators. These findings were important as they demonstrated the innocuousness of PVs for cells that are essential to cross-prime an adaptive immune response. The interaction of MVMp with DCs may even have a beneficial outcome. Indeed, MVMp infection resulted in a small but significant enhancement of CD80 and CD86 expression on mature LPS-stimulated myeloid and lymphoid DCs and also in the release of TNF-a and IL-6 from these cells. This stimulation was further increased if DCs were incubated with MVMp-infected glioma cells instead of being directly infected with PVs. Uninfected glioma cells, either intact or lysed, were less efficient than MVMpinfected GL261 cells in activating DCs. These data indicated that upon PV infection, permissive tumor cells released specific viral or cellular factors that were sensed by DCs and modulated their maturation. The nature of these factors deserves to be further investigated, as well as their recognition by surface or internal receptors displayed by APCs may mediate an adjuvant effect of PVs on adaptive anticancer immunity. Indeed, earlier studies by Moehler et al. 7 have shown that oncolysates generated through infection of human melanoma SK29-MEL cells with H1-PV (a rat PV closely related to MVMp) were more efficient in activating human DCs than lysates obtained by freezing/thawing. Furthermore, the DCs stimulated in this way were able to prime cytotoxic T lymphocyte clones to react against uninfected melanoma cells.
It was previously shown that MVMp does not replicate in MG and exerts no significant toxic effect on these cells even at high MOIs, failing to induce first-line MG activation reactions, that is, TNF-a production, inducible nitric oxide synthase expression and nitric oxide release. 18 In addition, the present study showed that untreated GL261 glioma cells---whether intact or F/T lysed---were also unable to stimulate MG, but that GL261 infected with MVMp cells still had acquired a significant capacity to activate MG, although to a lower extent than compared with DCs.
Two lines of evidence further support the role played by the adaptive immune system to enhance the PV-induced anticancer effects. On one hand, MVMp delayed but failed to suppress tumor formation from GL261 cell implants in RAG2 À/À mice, in contrast to the MVMp-dependent full elimination of tumors occurring in immunocompetent animals. Given that resistance to MVMp developed in GL261 cells under in vivo conditions (see above), these observations argue for a direct participation of immune effectors missing in RAG2 À/À immunodeficient mice (most likely T cells) in the MVMp-induced destruction of tumors. The faster growth and bigger size of GL261 tumors in RAG2 À/À compared with C57BL/6 mice indicated that the immune system did not prevent but acted as a brake on GL261 oncogenesis. Altogether, these results led us to propose that the above-mentioned immunomodulating effects of PV-infected glioma cells may synergize with the immune brake and convert it into efficient tumor rejection. On the other hand, the analysis of IFN-gproducing CD8
þ T cells and ELISPOT assays revealed that splenocytes from mice carrying MVMp-infected tumors were enriched in cells that were induced to release IFN-g after stimulation with uninfected GL261 cells, in comparison with control tumor-bearing animals. This difference further argues for the fact that MVMp infection of glioma cells enhances their capacity to stimulate a tumor-specific immune response mediated by T cells, as inferred from its defect in RAG2 À/À mice that lack these cells, but have functional natural killer cells, another antitumor effector cell population able to produce IFN-g. It should be stated that the s.c. route of transplantation used placed the tumor cells at an admittedly nonphysiological site for glioma to develop. This model was, however, relevant for the present proofof-concept demonstration of the impact of PVs on anti-tumor immune reaction. Indeed, in a therapeutic vaccination approach against intracranial GL261-derived tumors, depletion of either CD4 þ or CD8 þ T lymphocytes proved to impair the antitumor effect of the vaccine. 24 In conclusion, the present study shows that the interaction of PVs with cancer cells can lead not only to direct oncolysis, but also to a break of the immune tolerance to tumors, resulting in synergistic effects of virus infection and host immune reactions on tumor suppression. In at least some tumor models, as the one studied in this work, immune cells appear to be the main effectors of PV-dependent tumor destruction. The mechanism by which PVs tip the immune balance in favor of an antitumor T-cell response, and the precise actors of this response, remains to be identified. These questions are most interesting as they may help to understand and possibly to overcome some of the problems of anticancer vaccination strategies, such as the low immunogenicity and immunosuppressive environment of tumors and the subtle regulation of immune tolerance.
